Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
ArriVent BioPharma, Inc. (AVBP) Debt to Capital Ratio data is not available.
| Income Statement Financials | |
-- |
|
$-166.31M |
|
-- |
|
-- |
|
$177.53M |
|
$-177.53M |
|
$11.23M |
|
$-166.31M |
|
$-166.31M |
|
$-166.31M |
|
$-166.31M |
|
$-166.31M |
|
$-166.31M |
|
$-177.53M |
|
$-180.56M |
|
38.46M |
|
38.46M |
|
$-4.32 |
|
$-4.32 |
|
| Balance Sheet Financials | |
$332.90M |
|
-- |
|
$0.27M |
|
$333.17M |
|
$25.95M |
|
-- |
|
-- |
|
$25.95M |
|
$307.22M |
|
$307.22M |
|
$307.22M |
|
42.45M |
|
| Cash Flow Statement Financials | |
$-160.59M |
|
$-71.23M |
|
$203.06M |
|
$74.29M |
|
$45.54M |
|
$-28.75M |
|
$12.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.83 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-160.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.13% |
|
-54.13% |
|
-49.92% |
|
-54.13% |
|
$7.24 |
|
$-4.18 |
|
$-4.18 |
|